Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics director Michael Schmertzler reported new equity awards. On January 2, 2026 he received 8,000 shares of common stock in the form of restricted stock units at a price of $0, increasing his directly held common stock to 163,266 shares. The RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths vesting on January 2, 2027.
He was also granted a stock option for 6,950 shares of common stock with an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments starting on February 2, 2026. Both awards are reported as directly owned by Schmertzler.
PTC Therapeutics chief financial officer Pierre Gravier reported new equity awards. On January 2, 2026, he received 20,000 restricted stock units, which vest in four equal annual installments starting on January 2, 2027. His direct holdings of common stock totaled 92,449 shares after this grant, including shares previously acquired through the company’s employee stock purchase plan.
On the same date, he was also granted a stock option for 50,000 shares of common stock with an exercise price of $76.74 per share and an expiration date of January 1, 2036. This option vests over four years, with 25% vesting on January 2, 2027 and an additional 6.25% of the original grant vesting at the end of each successive three-month period beginning April 2, 2027.
PTC Therapeutics insider Matthew Klein has filed a Rule 144 notice to sell 5,149 shares of common stock. The planned sale is to be executed through Fidelity Brokerage Services, with an aggregate market value of $396,203.19, and an approximate sale date of January 6, 2026 on NASDAQ. The shares to be sold were acquired on January 5, 2026 through restricted stock vesting as compensation from the issuer.
PTC Therapeutics had 80,288,305 shares of common stock outstanding. Over the prior three months, Matthew Klein sold 3,428 shares for gross proceeds of $271,062.93 on December 2, 2025, and 8,089 shares for $619,921.55 on December 30, 2025. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
A holder of common shares of symbol PTCT has filed a Form 144 notice for a planned sale of 1,381 shares through Fidelity Brokerage Services on the NASDAQ. The filing lists an aggregate market value of $106,264.64 for these shares and notes that there were 80,288,305 shares outstanding at the time of the notice. The shares to be sold were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation, with payment also dated 01/05/2026.
A holder of PTCT common stock has filed a Form 144 notice to sell 1,739 common shares. The shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/06/2026. The filing notes an aggregate market value for this block of $133,811.88 and shows 80,288,305 common shares outstanding.
The 1,739 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, the same seller, identified as Mark Boulding, has reported multiple sales of PTCT common stock, including transactions on 10/06/2025, 10/07/2025, 11/17/2025, and 01/05/2026 with disclosed gross proceeds for each sale.
An insider of the issuer filed a notice of proposed sale of 1,789 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 01/06/2026, with the shares listed on NASDAQ. These shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the filing reports 80,288,305 common shares outstanding. Over the prior three months, Eric Pauwels reported selling common shares in three transactions totaling 40,290; 3,202; and 20,508 shares, for gross proceeds of $3,038,755.33, $240,354.49, and $1,584,387.54, respectively.
Neil G. Almstead filed a notice of proposed sale of 1,279 shares of common stock through Fidelity Brokerage Services LLC, with an approximate sale date of 01/06/2026 on NASDAQ. These shares were acquired as restricted stock vesting from the issuer on 01/05/2026 as compensation.
In the prior three months, Neil G. Almstead sold 35,572 common shares on 11/24/2025 for gross proceeds of
An insider has filed a notice to sell 2,266 shares of common stock through Fidelity Brokerage Services, with an aggregate market value of $172,216.00. The planned sale is targeted for 01/05/2026 on the NASDAQ market. These shares were acquired on 01/05/2026 via a stock option originally granted on 01/05/2023, and paid for in cash. In the past three months, the same person sold additional common shares in three transactions totaling several thousand shares, while total shares outstanding are 80,288,305.
PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.
PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.
The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.